No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 1 trial shows loncastuximab tesirine demonstrated significant response rates and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

byKathleen Lau

May 21, 2021

in StudyGraphics

Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials

RelatedReports

Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization

Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026

Intrapartum serum prolactin may predict risk of postpartum diabetes

Chronic Disease

Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy

March 26, 2026

Esmolol-induced heart rate reduction may aid in septic shock

Survivors of intensive care unit admissions may have increased risk of self-harm and suicide

Being overweight and obese associated with increased incidence of chronic kidney disease

2 Minute Medicine Rewind May 24, 2021

Standardized developmental screening of refugee children is recommended

Hand hygiene intervention to optimise soil-transmitted helminth infection control among primary school children found to be not effective

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports